Agfa's Cloud Pivot Accelerates, but the Real Story Is a Potential Healthcare IT Carve-out

Agfa-Gevaert's second-quarter results read as a company in the middle of a deliberate, three-pronged transformation: a legacy film business that is stabilizing through aggressive cost cuts, a Healthcare IT unit that is pivoting hard to the cloud, and a green-hydrogen membrane (ZIRFON) that is in a temporary trough. The headline surprise is not the numbers — adjusted EBITDA was “solid” but unspectacular, and free cash flow remained negative — but the accelerating pace of the strategic shift and the mounting hints that a carve-out of Healthcare IT may soon be on the table.

Cloud transition wins orders, loses near-term revenue

The most striking data point is the order intake mix in Healthcare IT. “our order intake was 50% cloud-based during the quarter” — Pascal Juery, CEO · 2026-08-26 — a step change that management explicitly framed as a sign of market-share gains. Indeed, “54% of our order intake is with net new customers, meaning we are winning share” — Pascal Juery, CEO · 2026-08-26 against the incumbents. This is exactly the kind of momentum that underpins a bullish long-term story: the pivot to subscription is the right move for recurring value, but it mechanically depresses current revenue and margin recognition. CFO Fiona Lam acknowledged this trade-off, noting that cloud transformation “delays revenue and margin recognition,” and yet the underlying quality of the order book is improving.

The company’s own keyword trajectory reflects this ongoing narrative. The term cloud transition has been a recurring theme for the past four quarters, but the language has escalated from “transition” to outright acceleration. In the prior call (Q1 2026), the same phrase appeared but with a more cautious tone; now the CEO says “this momentum is really accelerating quarter-after-quarter.” — Pascal Juery, CEO · 2026-08-26 The analyst response has evolved accordingly: rather than questioning the strategy, the questions have shifted to how AI will be financed and whether the cloud architecture can integrate third-party applications — the latter confirmed by Pascal Juery with a simple “Yes. Absolutely.” — Pascal Juery, CEO · 2026-08-26

ZIRFON: a trough, but rebound in sight

The other growth engine, Green Hydrogen Solutions, is having a difficult 2026. CEO Pascal Juery described it as “a bit of a lost year for ZIRFON” because customers have already built inventories and are waiting for project FIDs. But he was emphatic about the medium-term rebound:

ZIRFON is not having a good year, but stay tuned. It is going to change very rapidly in '27, and the technology is confirmed to be the top class and the reference technology for membranes in the hydrogen world.

The Green Hydrogen Solutions weakness is partially offset by the strong performance of DPS (Digital Printing Solutions), which returned to double-digit growth. Management credits high-end demand and ink volumes, and the segment’s turnaround is a bright spot in an otherwise mixed portfolio.

Film: the quiet hero

The most surprising contributor to the quarter was the legacy film business. Despite ongoing volume decline, restructuring efforts have allowed the segment to claw back profitability. CFO Fiona Lam said: “we are specifically pleased with 11% growth on DPS, although still not sufficiently offsetting the decline of Green Hydrogen Solutions.” — Fiona Lam, CFO · 2026-08-26 But the bigger note is that volume decline in film has been more than compensated by pricing and cost savings. The company has navigated extreme silver price volatility and is now proactively managing silver-based pricing. The profitability of film has turned the corner, and the executive team is confident that full-year film profitability will be better than last year.

This is a classic example of a mature business being run for cash and stability, and it provides the necessary funding for the growth engines. Yet the market’s attention is on the transformation, not the legacy. The company’s own transformation program has now delivered more than €60 million in annualized savings, and management emphasizes it is self-funding.

Cash, debt, and the looming strategic question

The financial position is stable but stretched. Free cash flow was negative €10 million in the quarter, largely due to restructuring payouts, and net financial debt rose to €74 million. Leverage is still comfortable at 1.4x adjusted EBITDA, and covenant headroom exists. The CFO pointed to a large quarterly cash out for the Moonshot program, but insisted the annual cost is under control.

Perhaps the most intriguing development is the appointment of a new CFO (Declan Guerin) and a new director (Kurt Decat), both with backgrounds in carveouts and private equity. When an analyst asked directly whether their experience could “lead the way for HealthCare IT,” the CEO did not deny it but deflected: “I'm not going to comment on that. Clearly, the first priority we have for HealthCare IT today is to succeed the cloud transition.” — Pascal Juery, CEO · 2026-08-26 He also added that “we might look at strategic options” — a phrase that will not go unnoticed by investors. The company’s keyword list for 2026 includes “new CFO” and “Net new customers,” but the real story is the potential monetization of the healthcare IT asset once its cloud transition is further along.

Overall, Agfa is a small-cap name with a clear, if multi-year, transformation plan. The quarter was operationally solid, and the order book signals a brighter future for Healthcare IT, but the market is likely to keep pricing in the timing of that carve-out event. As the CEO concluded, “nothing is broken with the growth engines on the contrary.” — Pascal Juery, CEO · 2026-08-26 The market will have to be patient; the direction, however, is unmistakable.